Journal of Viral Hepatitis

Article	Citations
Issue Information	39
Age, ethnicity and proximity to clinic determine retention in care of chronic hepatitis B patients	36
Response to letter to editor: Potential impact of Helicobacter pylori infection on hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B	31
	31
Issue Information	28
Issue Information	27
Long‐Term Effects of Direct‐Acting Antivirals on Hepatitis C: Trends in Liver Disease–Related Hospitalisations in Italy	27
Optimization of the Use of APRI and FIB‐4 for Ruling Out Liver Cirrhosis in Chronic Hepatitis B Patients With Normal Alanine Aminotransferase	26
Australian Community Pharmacists' Preparedness to Offer and Discuss Hepatitis C Testing and Treatment With Pharmacy Clients: A Representative Cross‐Sectional Survey	23
Retraction	22
Correlates of chronic hepatitis B virus infection in the general adult population of China: Systematic review and meta‐analysis	20
Individual Heterogeneity and Trends in Hepatitis C Infection Risk Among People Who Inject Drugs: A Longitudinal Analysis	20
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST‐HCV cohort	19
Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B	17
Analytical validation of hepatitis B core‐related antigen (HBcrAg) using dried blood spots (DBS)	17
Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England	17
Reduction in hepatitis C‐related hospitalizations after the implementation of the Strategic Plan for Tackling Hepatitis C in the Spanish National Health System: regional level differences	16
Depletion of circ_0088046 suppressed cell growth and motility of hepatocellular carcinoma via circ_0088046‐miR‐1299‐RTKN2 ceRNA pathway	16
Hepatitis B virus reactivation in cancer patients receiving direct‐acting antivirals for hepatitis C virus infection	16
	15
	15
Issue Information	15
Evaluating and communicating hepatitis C cascades of care data in Tayside, Scotland: A journey towards elimination	15
Issue Information	15
Issue Information	14

Quantitative HBsAg an unreliable marker for diagnosis and disease progression in genotype F chronic HBeAg‐negative infections	14
Sequence characterization of extracellular HBV RNA in patient plasma	14
Cover image	14
Patient‐reported experiences with direct acting antiviral therapy in an integrated model of hepatitis C care in homeless shelters	14
Follow‐up evaluation of patients with liver test abnormalities detected during SARS‐CoV2 infection	14
Cover Image	13
A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C	13
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwid	13
Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents	13
	13
A morphometric analysis of hepatitis B subviral particles shows no correlation of filament proportion and length with clinical stage and genotype	13
Changes in the estimated renal function after hepatitis C virus eradication with direct‐acting antiviral agents: Impact of changes in skeletal muscle mass	12
Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib	12
‘There's too much power in this number. It's freaking the whole response out’: The views of key informants on evidence and targets to achieve hepatitis C elimination goals in Australia	12
Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B	12
International disease burden of acute viral hepatitis among adolescents and young adults: An observational study	12
Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non‐cirrhotic HBeAg‐positive chronic hepatitis B	11
Different mutation rates in the basal core promoter and precore regions between hepatitis B virus subgenotype F1b clusters	11
	11
	11
240‐week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C	11
Assessing risk scores for predicting hepatocellular carcinoma in Thai patients with chronic hepatitis B	11
Poor linkage to care may compromise the Brazilian plan for hepatitis C elimination	11
A Programme of Hepatitis C Surveillance With Active Linkage to Care (HEAL) for Inpatients in Two Tertiary Hospitals in Jiangsu, China	10
Prevalence of hepatitis B virus (HBV) and latent tuberculosis co‐infection and risk of drug‐induced liver injury across two large HBV cohorts in the United	10
Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues	10
Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy	10
Issue Information	10
Sustained and cumulative impact of an electronic medical record‐based alert on a hepatitis C birth cohort screening programme	10
Efficacy and Safety of Tenofovir Amibufenamide and Tenofovir Alafenamide for First‐Time HBV‐Related Decompensated Cirrhosis	10
Post‐HCV cure self‐reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH)	10
The role of serum sphingolipids as potential biomarkers of non‐response to direct acting antiviral therapy in chronic hepatitis C virus infection	9
Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study	9
Death certificates compared to SEER‐Medicare data for surveillance of liver cancer mortality due to hepatitis B or hepatitis C infection	9
	9
Hepatitis A occurrence and outbreaks in Europe over the past two decades: A systematic review	9
	9
Persistence of antibodies 5 years after hepatitis B vaccination in preterm birth children: A retrospective cohort study using real‐world data	9
Persistence of immunity against hepatitis A in Brazilian children vaccinated with a single dose of inactivated virus vaccine	8
A novel multi‐epitope peptide vaccine candidate targeting hepatitis E virus: An in silico approach	8
Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease	8
Large‐scale screening is not useful for identifying individuals with hepatitis B or C virus infection: A prospective Swiss study	8
A cross‐sectional study of hepatitis C prevalence and correlates among persons who inject drugs in rural and non‐rural communities	8
Hepatitis C treatment in a co‐located mental health and alcohol and drug service using a nurse‐led model of care	8
Prevalence, clinical and virological characteristics and short‐term prognosis of hepatitis delta infection among patients with HIV/HBV in Nouakchott, Mauritania	8
Contextual and individual factors associated with knowledge, awareness and attitude on liver diseases: A large‐scale Asian study	8
Hepatitis C prevalence and elimination planning in Pakistan, a bottom‐up approach accounting for provincial variation	8
Hepatitis B virus–induced hepatocarcinogenesis: A virological and oncological perspective	8
The cost‐effectiveness of case‐finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK	8
The impact of point‐of‐care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study	8

Issue Information	8
Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C	7
Closing the hepatitis C treatment gap: United States strategies to improve retention in care	7
The impact of the first, second and third waves of covid‐19 on hepatitis B and C testing in Ontario, Canada	7
Prevalence and characteristics of hepatitis C virus infection detected by extended screening of working‐age adults in Madrid (Spain)	7
Classification and survival prediction in early‐stage cirrhosis by gene expression profiling	7
Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV‐infected people on opioid agonist therapy	7
Prognosis of hepatitis E infection in patients with chronic liver disease: A meta‐analysis	7
Falling treatment uptake in the hepatitis C care cascade is a growing threat to achieving elimination	7
Hepatitis A hospitalisations in the United States and risk factors for inpatient mortality: A nationwide population study, 1998–2020	7
Reply to: ‘Long‐term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus‐related decompensated cirrhosis’	7
Bulevirtide‐based treatment strategies for chronic hepatitis delta: A review	7
External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals	7
Genetic substructure and host‐specific natural selection trend across vaccine‐candidate ORF‐2 capsid protein of hepatitis‐E virus	7
Internet‐guided HCV‐RNA testing: A promising tool to achieve hepatitis C micro‐elimination among men who have sex with men	7
High prevalence of hepatitis B virus among MSM living with HIV in India	7
Kinetics of serum O‐glycosylated M‐hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients	7
Viral hepatitis C pandemic: Challenges and threats to its elimination	7
	7
Impact of treatment with direct‐acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co‐infected individuals	6
Interaction Between Hepatitis B, Hepatitis C and Alcohol in the Development of Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis	6
Immunogenicity of a Birth Dose of Hepatitis B Vaccine in Kinshasa, Democratic Republic of Congo: A Randomised, Controlled Trial	6
Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis	6
Global prevalence of occult hepatitis B: A systematic review and meta‐analysis	6
Self‐reported hepatitis B testing among noninstitutionalized adults in the United States before the implementation of universal screening, 2013–2017: A nationwide population‐based study	6
Baseline Alpha‐Fetoprotein Elevation and the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B: A Multicentre Cohort Study	6
Letter in response: Psychiatrists can treat hepatitis C	6
Psychiatrists can treat hepatitis C	6
Only partial improvement in health‐related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real‐world setting—results from the German Hepatiti	6
Migrants and hepatitis: A tale of two worlds	6
Hepatocellular carcinoma among patients with chronic hepatitis B in the indeterminate phase	6
Evaluation of Knowledge, Attitudes and Practices for Hepatitis B Virus Infection Among Primary Healthcare Physicians in Georgia	6
Outcomes of a 1‐Year Pilot Study Implementing Universal Hepatitis Delta Virus Testing Among Veterans With Chronic Hepatitis B	6
Implementation of a re‐linkage to care strategy in patients with chronic hepatitis C who were lost to follow‐up in Latin America	6
Long‐term persistence of anti‐HAV antibody conferred by a single dose of live‐attenuated hepatitis A vaccine: Results from 17‐year follow‐up	6
Severe Liver‐Related Outcomes in Patients With Hepatitis Delta: Results From a Multi‐Ethnic Multicenter Long‐Term Follow‐Up Study	6
Substance use and CD4/CD8 ratio in HIV/HCV co‐infected people receiving direct‐acting antiviral treatment (ANRS CO13 HEPAVIH): Authors' reply	6
Mean HBsAg decline at week 24 of PEG‐IFN‐based treatment predicts subsequent rate of HBsAg clearance — suggesting a valuable endpoint for early development HBV trials	6
Impact of direct‐acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta‐analysis	6
Issue Information	6
The benefits of gene therapy in people with haemophilia	6
Cost‐effectiveness analysis of an active search to retrieve HCV patients lost to follow‐up (RELINK‐C strategy) and the impact of COVID‐19	6
Clinical Prevalence of Hepatitis D Virus Among Hepatitis B Patients in Sulaymaniyah Governorate, Northern Iraq	6
Global elimination of HBV: Is it really achievable?	6
Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection With Interferon or Direct Antiviral Therapy	6
A novel non‐invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD	6
Direct‐acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment	5
The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis	5
Temporal and geographic spreading of hepatitis B virus genotype A (HBV‐A) in Brazil and the Americas	5
More intensive hepatitis C virus care models promote adherence among people who inject drugs with active drug use: The PREVAIL study	5
Improvement of chronic HCV infection‐related depression, anxiety, and neurocognitive performance in persons achieving SVR‐12: A real‐world cohort study	5
Health service utilization and experiences of stigma amongst people who inject drugs in Melbourne, Australia	5
	5
	5
HBV pgRNA profiles in Chinese HIV/HBV coinfected patients under pre‐ and posttreatment: a multicentre observational cohort study	5
Chronic hepatitis B beyond clinical burden: Psychosocial effects and impact on quality of life	5
Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful	5
Effectiveness of direct‐acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real‐world cohort (REACH‐C)	5
Prevalence of hepatitis E infection among adults with concurrent chronic liver disease	5
Contribution of alcohol use in HIV/hepatitis C virus co‐infection to all‐cause and cause‐specific mortality: A collaboration of cohort studies	5
Factors influencing compliance with Hepatitis C treatment in patients transitioning from prison to community—A summary scoping review	5
Retreatment for hepatitis C virus direct‐acting antiviral therapy virological failure in primary and tertiary settings: The REACH‐C cohort	5
Symptoms and functioning improve after chronic hepatitis C cure as assessed by the Memorial Symptom Assessment Scale and PROMIS measures	5
Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000‐Korean outcome study	5
Monkeypox outbreak as an opportunity to identify new cases of HCV infection in limited resource settings	5
Testing to sustain hepatitis C elimination targets in people who inject drugs: A network‐based model	5
	5
Issue Information	5
Delta hepatitis epidemiology and the global burden of disease	4
Knowledge, perception and expectation of management of hepatitis B infection among pregnant hepatitis B carriers in Hong Kong	4
Shear wave elastography: How well does it perform in chronic hepatitis D virus infection?	4
Randomized clinical trial: Direct‐acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed therapy versus fortnightly c	4
Issue Information	4
Which patients should be considered for gene therapy	4
Research progress on detection methods for hepatitis B virus covalently closed circular DNA	4
Prevalence and determinants of hepatitis delta virus infection among HIV/hepatitis B‐coinfected adults in care in the United States	4
Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta‐analysis	4
	4
Issue Information	4
Comment on ‘Long‐term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus‐related decompensated cirrhosis’	4

Cure everyone and vaccinate the rest: The patient perspective on future hepatitis B treatment	4
Soluble inflammatory mediators identify HCV patients who may be cured with four weeks of antiviral treatment	4
Chronic viral hepatitis C micro‐elimination program using telemedicine in Guigang city	4
Patient‐reported outcomes of the Treatment and Prevention Study: A real‐world community‐based trial of direct‐acting antivirals for hepatitis C among people who inject drugs	4
Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days	4
Association of HBeAg decline rate from mid‐pregnancy to delivery with HBeAg seroconversion after delivery in hepatitis B virus‐infected mothers	4
Predictors of engagement in screening for a hepatitis C virus (HCV) treatment trial in a rural Appalachian community	4
Abnormal liver function tests and coronavirus disease 2019: A close relationship	4
Hepatitis after gene therapy, what are the possible causes?	4
Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts	4
Issue Information	4
Development of monoclonal antibodies to target the large surface protein of hepatitis B virus and their use in therapeutic and diagnostic applications	4
Context‐dependent accuracy of the cobas plasma separation card for HCV RNA viral load measurement	4
	4
Sex‐related difference analyses of efficacy and safety in clinical trials of direct‐acting antivirals to treat chronic HCV genotype 1 and 3 infections	4
	4
	4
Safety, pharmacokinetics and antiviral activity of ABI‐H2158, a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study	4
Targeted antiviral treatment of hepatitis B virus in culturally and linguistically diverse populations to achieve elimination targets in Australia	4
Incidence of post‐transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection	4
The elimination of hepatitis D as a public health problem: Needs and challenges	4
	4
Issue Information	4
	4
Issue Information	4
Issue Information	4
Epidemiology estimates of hepatitis D in individuals co‐infected with human immunodeficiency virus and hepatitis B virus, 2002–2018: A systematic review and meta‐analysis	4
Uptake of interferon‐free DAA therapy among HCV‐infected decompensated cirrhosis patients and evidence for decreased mortality	4
Prevalence of hepatitis C among pregnant women in an Appalachian population	4
Geographic variation in HCV treatment penetration among people who inject drugs in Baltimore, MD	4
Issue Information	4
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B	4
Elevation of S2‐bound α1‐acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma	4
Withdrawal: CircKIAA1429 accelerates hepatocellular carcinoma advancement by miR‐199b‐5p/OTX1 pathway, by Bin Lu, Min Cheng, Tao Wang	4